Danaher Buys Biopharma Business from General Electric
GE shares rocketed after industrial conglomerate Danaher agreed to buy biopharma business for $21.4 billion. Analysts claim that GE will strongly benefit from this deal by spending the money they raised to reduce the existing company's debts. In 2019 GE Biopharma's revenue is estimated to reach $3,2 billion. Danaher's shares increased in price too — but only by 5,2%.